About Guanine nucleotide-binding protein G(olf) subunit alpha
Guanine nucleotide-binding protein G(olf) subunit alpha (GNAL) is a protein
from Homo sapiens identified by UniProt accession
P38405, 381 residues long.
MolForge cross-references it against 0 known binders and
85 disease associations.
Target properties
| Protein name | Guanine nucleotide-binding protein G(olf) subunit alpha |
| UniProt accession | P38405 |
| Gene | GNAL |
| Organism | Homo sapiens |
| Length | 381 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (85)
Diseases linked to this target (Open Targets).
- dystonia 25 · score 0.69
- Autosomal dominant focal dystonia, DYT25 · score 0.55
- Dystonia · score 0.54
- dystonic disorder · score 0.53
- DNA methylation · score 0.34
- thyroid gland adenocarcinoma · score 0.27
- Dysarthria · score 0.26
- Limb dystonia · score 0.26
- cholesteryl ester 16:0 measurement · score 0.22
- hepatocellular carcinoma · score 0.19
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P38405-F1 | alphafold | PREDICTED | 93.12 | — |
Amino-acid sequence (381 residues)
MGCLGGNSKT TEDQGVDEKE RREANKKIEK QLQKERLAYK ATHRLLLLGA GESGKSTIVK QMRILHVNGF NPEEKKQKIL DIRKNVKDAI VTIVSAMSTI IPPVPLANPE NQFRSDYIKS IAPITDFEYS QEFFDHVKKL WDDEGVKACF ERSNEYQLID CAQYFLERID SVSLVDYTPT DQDLLRCRVL TSGIFETRFQ VDKVNFHMFD VGGQRDERRK WIQCFNDVTA IIYVAACSSY NMVIREDNNT NRLRESLDLF ESIWNNRWLR TISIILFLNK QDMLAEKVLA GKSKIEDYFP EYANYTVPED ATPDAGEDPK VTRAKFFIRD LFLRISTATG DGKHYCYPHF TCAVDTENIR RVFNDCRDII QRMHLKQYEL L
Explore Guanine nucleotide-binding protein G(olf) subunit alpha with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets